CONTEXT: Previous studies have shown that Cry61, a cysteine-rich gene, can induce angiogenesis to improve arterial flow in rabbits with ischemic limb disease. A swine study demonstrated that neovasculature resulting from the infusion of the gene boosts myocardial blood flow to treat myocardial infarction. Nuclear physician Dr. Pascal Merlet and colleagues in the nuclear medicine department of Hopital Bichat in Paris and the cardiology department of Hopital Universitaire Henri Mondor in Creteil, France, performed the experiment.
RESULTS: Seven pigs with artificially produced myocardial infarction were treated with an epicardial injection of 5 x 108 infectious units of an adenovirus carrying the therapeutic Cyr61 gene. As a control, seven other pigs with artificial infarcts received adenovirus without the agent. Stress-rest technetium-99m sestamibi SPECT perfusion performed four weeks later found a significant decrease in the extent and mean intensity of ischemic defects in the animals treated with the Cyr61 gene compared with the controls (p = 0.02).
IMPLICATIONS: Merlet concluded that the Cyr61 gene transfer stimulates myocardial angiogenesis, prompting great improvement in myocardial perfusion measured with standard SPECT imaging. The findings strengthen the case for Cyr61 as a therapeutic candidate to reverse severe myocardial ischemia.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.